Filing Flows › Tonix Pharmaceuticals Holding (TNXP) › Q4 2024
Tonix Pharmaceuticals Holding (TNXP) Q4 2024 earnings results (fourth quarter 2024)
10-K filed Mar 18, 2025
Tonix Pharmaceuticals Holding (TNXP) reported revenue of $2.6M for the fourth quarter 2024 (Q4 2024), -32% from a year earlier and -9% from the quarter before. Operating margin was -870.6%, net loss $22.1M (856.2% of revenue).
Tonix Pharmaceuticals Holding, Q4 2024: revenue $2.6M (-32% year over year), operating margin -870.6%, net loss $22.1M, operating cash flow −$14.6M. The chart follows the revenue to costs, profit and cash.
| Q4 2024 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $2.6M | -9% | -32% |
| Operating profit | −$22.5M | — | — |
| Net earnings | −$22.1M | — | — |
| Operating cash flow | −$14.6M | — | — |
What changed
Revenue was $2.6M in Q4 2024, down 32% year over year and down 9% from the previous quarter. Zembrace Symtouch was the largest line at 96% of revenue.
Operating costs exceeded revenue by $22.5M, an operating margin of -870.6%. Total costs fell 19% while revenue fell 32%. The fastest-growing cost line was SG&A (+34%). The quarter ended with a net loss of $22.1M, wider than the previous quarter's $14.2M loss.
Operating cash flow was −$14.6M. Non-cash charges added back $496K of depreciation and amortization and $894K of share-based compensation. Working capital and other items added $6.1M. Capital expenditures of $3K exceeded it, leaving free cash flow of −$14.6M.
Questions
What was Tonix Pharmaceuticals Holding's revenue in the fourth quarter 2024?
Tonix Pharmaceuticals Holding (TNXP) reported revenue of $2.6M for the fourth quarter 2024 (Q4 2024), -32% from a year earlier and -9% from the quarter before.
Was Tonix Pharmaceuticals Holding profitable in the fourth quarter 2024?
Operating loss was $22.5M (-870.6% of revenue) and net loss $22.1M.